Cyclo-Oxygenase-2 Inhibitors and the Kidney: A Case for Caution

ISSN： 0114-5916

Source： Drug Safety, Vol.25, Iss.3, 2002-01, pp. : 165-172

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Balancing Gastroprotection and Cardioprotection with Selective Cyclo-Oxygenase-2 Inhibitors: Clinical Implications

By Meagher E.A.

Drug Safety, Vol. 26, Iss. 13, 2003-01 ,pp. : 913-924

Adis International

Access to resources Recommend Favorite

Cyclo-Oxygenase-2 Inhibitors: Rationale and Therapeutic Potential for Alzheimers Disease

By McGeer P.L.

Drugs & Aging, Vol. 17, Iss. 1, 2000-07 ,pp. : 1-11

Adis International

Access to resources Recommend Favorite

Assessment of the safety of selective cyclo-oxygenase-2 inhibitors: where are we in 2003?

By Yuan Yuhong Hunt Richard H.

Inflammopharmacology, Vol. 11, Iss. 4-6, 2003-12 ,pp. : 337-354

VSP

Access to resources Recommend Favorite

Upper gastrointestinal adverse drug reactions and cyclo-oxygenase-2 inhibitors (celecoxib and rofecoxib): a case/non-case study from the French Pharmacovigilance Database

By Lugardon S. Lapeyre-Mestre M. Montastruc J.

European Journal of Clinical Pharmacology, Vol. 60, Iss. 9, 2004-11 ,pp. : 673-677

Springer Publishing Company

Access to resources Recommend Favorite

New Dosage Formulations for Targeted Delivery of Cyclo-Oxygenase-2 Inhibitors: Focus on Use in the Elderly

By Bansal Shyam S.

Drugs & Aging, Vol. 24, Iss. 6, 2007-01 ,pp. : 441-451

Adis International

Access to resources Recommend Favorite